Table 1

Characteristics of studies included in the meta-analysis for an association between CYP1B1 L432V SNP and risk of urinary cancer
First author, year Country Ethnicity Source of control Cases/controls MAF of controls Powera Source of DNA Genotyping methods
Prostate cancer
Holt, 2013 USA Caucasian PB 1256/1235 0.41 1 blood SNPlex
Catsburg C, 2012 USA Caucasian PB 1433/760 0.47 1 blood Taqman
Beuten J, 2008 USA Caucasian PB 649/738 0.39 1 blood Taqman
Berndt, 2007 USA Mixed PB 486/611 0.47 1 blood TaqMan
Cussenot O, 2007 France Caucasian HB 1053/837 0.39 1 blood TaqMan
Sobti RC, 2006 India Asian PB 100/100 0.18 0.415 blood PCR–RFLP
Cicek MS, 2005 USA Mixed HB 439/479 0.47 1 blood PCR–RFLP
Fukatsu, 2004 Japan Asian HB 136/255 0.29 0.947 blood PCR–RFLP
Chang BL, 2003 USA Mixed HB 310/182 0.44 0.807 ND Sequencing
Tanaka Y, 2002 Japan Asian PB 117/200 0.18 0.857 ND AS-PCR
Bladder cancer
Berber U, 2013 Turkey Asian PB 114/114 0.27 0.499 tissue AS-PCR
Salinas-Sánchez AS, 2012 Spain Caucasian HB 208/208 0.39 0.875 blood Sequencing
Fontana L, 2009 France Caucasian HB 51/45 0.58 0.104 blood TaqMan
Figueroa J, 2008 Spain Caucasian HB 1084/1012 0.42 1 blood/buccal TaqMan
Hung RJ, 2004 Italy Caucasian HB 201/214 0.59 0.888 ND PCR–RFLP
Renal cancer
Salinas-Sánchez AS, 2012 Spain Caucasian HB 126/208 0.39 0.875 blood Sequencing
Sasaki M, 2005 USA Asian HB 211/200 0.18 0.857 tissue AS-PCR

Abbreviations: SNP Single nucleotide polymorphism, HB Hospital based, PB Population based, RFLP Restriction fragment length polymorphisms, AS-PCR Allele specific PCR, ND Not described. aStatistical power to detect an OR of 1.5 (or 0.67 = 1/1.5).

Jiang et al.

Jiang et al. Diagnostic Pathology 2014 9:113   doi:10.1186/1746-1596-9-113

Open Data